Latest News Jan 09, 2023 Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable Download Share Facebook Twitter LinkedIn Email View all Press Releases Upcoming Events More events are coming soon. View all Events Stock Quote Price Change Volume Feb 2, 2023 2:28 AM EST Data Provided by Refinitiv. Minimum 15 minutes delayed.